HUE028021T2 - 3-as toll-szerû receptor antagonisták - Google Patents

3-as toll-szerû receptor antagonisták Download PDF

Info

Publication number
HUE028021T2
HUE028021T2 HUE10770329A HUE10770329A HUE028021T2 HU E028021 T2 HUE028021 T2 HU E028021T2 HU E10770329 A HUE10770329 A HU E10770329A HU E10770329 A HUE10770329 A HU E10770329A HU E028021 T2 HUE028021 T2 HU E028021T2
Authority
HU
Hungary
Prior art keywords
ser
leu
gly
val
thr
Prior art date
Application number
HUE10770329A
Other languages
English (en)
Inventor
Mark Cunningham
Yiqing Feng
Katharine Heeringa
Jinquan Luo
Robert Rauchenberger
Mark Rutz
Mateo Lani San
Robert T Sarisky
Raymond Sweet
Fang Teng
Alexey Teplyakov
Sheng-Jiun Wu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/609,675 external-priority patent/US8409567B2/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of HUE028021T2 publication Critical patent/HUE028021T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)

Claims (3)

  1. Szstfeatiklmi y
    1, Izolált $3e&amp;ppjg vagy Iragmetise, skol az ellenanyag köti -«#8S toeepitm C1B&amp;3) &amp;M<| 1D NO: 2 szerinti KAIN R41R 1,444, N44L E442, Y465, N466, K467, Y468. R488, R489, A49i, K493, N5IS, MS16, NS i 7, M539.14441. SS? R L594
  2. 2, Az L igéSyporii; szkíioti »iáit elemtsyag, álól az ejlfeíiaítyág §M|"!i> MO: Í2, 86 és $4 szerinti aminesav-szekvencsája 1-es, 2-es és 3-as nehézíánc kompletnemantásí meghatározó régiót (HCDRi HCDR2. 140DR3) és SEO ií.> NO: 7% SÖ és |7 szerinti »htossy-szekvésOáp l-es, Z*es és 3-as áötmyőJáöe ktanpietnemarkást meghatározó régiói (LCÛR! ECDR2, LC;PR3j tartalmaz, és továbbá óivá« könnyítláító: steégiot: tartalmaz, amely legalább 9&amp;%~km azottos a kappa :I vázregió (VkI) .kötmyőláns variábilis régió emiïmsiîv-szekvettcitpval és olysm nehézláne vázrégiói tartalmaz, amely legalább 9iMs~bm moms a ¥8S. vázrégió (VM) neisézlárte variábilis régió ssainosav-szekveneiáiéval. ;i A 2. Igénypont szerinti izolált ellenanyag, almi a Vk 1 vázrégsói az 1GK.V 1.-39401 kódolja, amelynek az aarinosav-szekvaneiáját a SEQ 1D NO: 221 mutatja. és ahol a Vid vázrégiét: tsz IGHV5-51*öi kódolja, amelynek az aniiivesav-szekvettotájáí a SEQ 1:0:2¾¾ 222 mulatja, 4 A 3. Igénypont szetait IÄt ellmiátpig, »Oy Az SE(| ID NORD ó szerinti «iitosay-s«kvébeialú nehézláim lü répát és SBO P NO:4l szerinti aisiAósav-székyetietáiú köniiyőláíto variábilis régiót tartalmaz, S. Az előző igénypontok bármelyike szerinti izolált éíkmányag, aboi az ellenanyag a kővetkező éríajdonságok közli í legalább eggyel rendelkezik; a, kötődik akimén ÍÍ.R34kv? <10 nM ÖA44 b, csökkenti a ilmmás TRR3 biológiai aktivitásáé >5Ü9eml 1 ßg'mi: :fee««lbiNI?'t6bsá8. ,84*$^ NF-kB rijsartergén vizsgálati eprasbao; e. gátolja az IL-é vagy eRDLM/IP-lö. termelődést >6ő%-ai lő Agitál kwéMstéta. <1M agM: ipoílCJt^yei stímniák BBAS-2B sipmkbőí; d, gátolta az 11,6 vagy OXCldtl/lPOŐŐ termelődést >38%-al 8S4 ygÁni koooesírádófesrt «100 ttglml |toii{t :03-vel stimulált BBAS-zlks^ekbdí:; e. gátolja az íL-ő tsrxneledesi ASÖ%-al 4 Mg/iol koneerarácáoban 62,5 ngónl pölgRO^vel Minwsláit MIBE sejtekből; C gátolja az TL-ő termeíöőést >5Ő%saí 1 pg/nd koncentrációban 62,5 ngémi polit t:C)-vel stirmBáii NHBE sejieklxd; g. gátolja PBMC f»li(! :C>indak:áít tFN-γ. ÍL-ó vagy ü,-i2 ietrneiéséi >2Ő%-ai i agőtt! kooceitirációban: a. gstelis a Oynomologtts TÖ13 biologtai aktivitását <M gg/ml 1C5Ö értékkel to vtoaj NF-kB riportergén vizsgáíai; eliárásban; vagy i, gátolja a Cynonmlögtis :||;R3 biológiái aktivitását <5 pgAni ICSíi: értékkel: m v&amp;m ISRB ripsïttergén vizsgálat i eljárásban. 4 Azeiőzö igénvpofitok bát'ntelyike szérttitt izpiáit eliepanyág alsói áz ellenanyag a>,ie|ésersbaxnáa; b. humán-adaptált; ! e. poi ietiiài-glkolhoz feööjugáfí; d. îgCf4 IMpum; vagy e. sz Fc dómén S229P, P2.35A v&amp;gy 1,236.0 muîàddt hutaimaz:. ?, Az: előző igénypontok bármelyike szerinti Mai ellenanyag, moely S£Q ÍD NO:220 szedné M«Âv»â2eteeaei^i;8phéàâ8e0t «s Â| 1D M): 1 Sb szerinti â^Â^fbsxekv^^%l^ytlài&amp;Ci>i táMitukp % Ûÿ$jggêmÊ&amp; kéSgidsény, amely 1-7. igénypontok bármelyike s««Â izolált ellenanyagot vagy: tragmeost és gyógyászati lag Äpdhaid hordozót tartalmaz
  3. 9. Az !-?. igénypontok ban ne ly ike szétjntl Mai ellenanyag vagy a S. igénypont: szerinti gyógyászati készítmény a kővetkezőkben történő alirahnttzista: a) gyuíiadásns állapot kezelése, «ttot. a kezelés magúban foglalja m ellenanyag vagy gyógyászati készítmény terápiásán hatásos mennyiségének beadását arra szoruló páciensnek elegendő ideig ahhoz, hogy kezelje vagy megelőzze a gyttliadásos állapoiog például altől a gyulladásos állapot: $ gyulladásos pulmonáris állapot, ahol adott esetben a gyulladásos pulstöoárls állapot asztma, krónikus obstruktiv fphnonáris betegség fCObPj, légúti hlperérzékenvség, vagy-iM^típMibató flaetnophiíes mf^Mm Indukálja; il) gyulladásos béibetegség; in) antohtnuphetegság; ív) szisztémás gyulladásos állapig ahol adott esetben a szisztémás gyulladásos állapot estokln Mrm' szisztótpás gyulladásos yilasg szlndrima gmfovemts-host betegség (CWÄly, altul mspiraíorikns diszítessz szindróma (ÂRMj, súlyos. alul respitatortkus diszitessz szIntMng pMS j, kataszírötás ami-foszfollplíi: szindróma, súlyos vitális lérlózés,, atSluehss, tlMógyídládÚs. sokk vagy szepszis; vjreumatold tmhrilisa;: vagy yl) gaszMoteszílnáils, íefcéiyesedésse! kapcsolatos, àbol; adott, esetben: a: gaszúMtesztmálls lekèlyesedds fotiőző keiitisszei, Isémiás koiitisvzeL kölfe^éaes vagy Imfoellikus kolitisszel vagy nckrotizáló eoterokolitisszel kapcsolatos; h) íl-es típusú; eukditélégség, bipetgiikétniá :§hpi a kezelés magában fogtállá &amp;* ellenanyag gyogyászatt hdszlhnény terápiásán hatásos mennyiségének beadását ásza szoruló páciensnek elegendő ideig ahhoz, hogy kezelje a íl-es típusú cukorbetegséget, lúpergiíkétniát vagy híperitMinémiát; vagy c> vitfois fertőzések kezelése vagy otegeiőzése, almi a kezelés vagy rnegeíözés magában foglalja az elienanyág vM l^gyP?áÍ készlífoéúy terápiásat} hatásos mennyiségének beadM ttoá szoatló páciensnek elegendő me*g abhoz, hogy kezelje vagy megelőzze a vitális foriőzésékei, ahol adott esetben a virális fertőzés influenza \\t*os fertőzés.
HUE10770329A 2009-04-29 2010-04-29 3-as toll-szerû receptor antagonisták HUE028021T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17368609P 2009-04-29 2009-04-29
US12/609,675 US8409567B2 (en) 2008-10-31 2009-10-30 Toll-like receptor 3 antagonists

Publications (1)

Publication Number Publication Date
HUE028021T2 true HUE028021T2 (hu) 2016-11-28

Family

ID=43032773

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10770329A HUE028021T2 (hu) 2009-04-29 2010-04-29 3-as toll-szerû receptor antagonisták

Country Status (33)

Country Link
EP (2) EP3020822A1 (hu)
JP (1) JP5727463B2 (hu)
KR (2) KR101758713B1 (hu)
CN (1) CN102482699A (hu)
AU (1) AU2010241581A1 (hu)
BR (1) BRPI1016191A2 (hu)
CA (1) CA2760525A1 (hu)
CL (1) CL2011002703A1 (hu)
CO (1) CO6450607A2 (hu)
CR (1) CR20110642A (hu)
DK (1) DK2425008T3 (hu)
EA (1) EA021512B1 (hu)
EC (1) ECSP11011428A (hu)
ES (1) ES2556239T3 (hu)
HK (1) HK1170536A1 (hu)
HR (1) HRP20151352T1 (hu)
HU (1) HUE028021T2 (hu)
IL (1) IL215906A0 (hu)
ME (1) ME02280B (hu)
MX (2) MX2011011623A (hu)
MY (1) MY180699A (hu)
NI (1) NI201100187A (hu)
NZ (1) NZ596036A (hu)
PE (1) PE20121493A1 (hu)
PL (1) PL2425008T3 (hu)
PT (1) PT2425008E (hu)
RS (1) RS54451B1 (hu)
SG (1) SG175396A1 (hu)
SI (1) SI2425008T1 (hu)
SM (1) SMT201500293B (hu)
UA (1) UA112282C2 (hu)
WO (1) WO2010127113A2 (hu)
ZA (1) ZA201108724B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130090457A1 (en) * 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
HUE031756T2 (hu) 2008-10-31 2017-07-28 Janssen Biotech Inc TLR3-antagonisták
ES2543095T3 (es) * 2009-07-10 2015-08-14 Innate Pharma Agentes de unión a TLR3
EP2663329A2 (en) * 2011-01-12 2013-11-20 Innate Pharma Tlr3 binding agents
JP2014506259A (ja) * 2011-01-17 2014-03-13 ノヴォ ノルディスク アー／エス Ｉｌ−２１リガンド
CA2855955A1 (en) * 2011-09-12 2013-03-21 Janssen Biotech, Inc. Toll-like receptor 3 antagonists
AU2013269652B2 (en) * 2012-05-31 2017-07-06 Innate Pharma TLR3 binding agents
KR101878023B1 (ko) 2015-12-07 2018-07-16 현대자동차주식회사 차량용 전원 관리 시스템
CN113484526A (zh) * 2021-08-11 2021-10-08 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
CA2461315A1 (en) * 2001-10-05 2003-04-17 Coley Pharmaceutical Gmbh Toll-like receptor 3 signaling agonists and antagonists
JP2004016021A (ja) * 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
TWI487535B (zh) * 2004-11-30 2015-06-11 Centocor Inc 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
JP5199878B2 (ja) * 2005-10-27 2013-05-15 セントカー・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター、方法および用途
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
HUE031756T2 (hu) * 2008-10-31 2017-07-28 Janssen Biotech Inc TLR3-antagonisták

Also Published As

Publication number Publication date
WO2010127113A2 (en) 2010-11-04
ZA201108724B (en) 2013-06-26
HK1170536A1 (zh) 2013-03-01
JP5727463B2 (ja) 2015-06-03
CO6450607A2 (es) 2012-05-31
BRPI1016191A2 (pt) 2020-12-08
ECSP11011428A (es) 2012-02-29
MX349056B (es) 2017-07-06
KR20170018110A (ko) 2017-02-15
CR20110642A (es) 2012-07-16
RS54451B1 (en) 2016-06-30
ES2556239T3 (es) 2016-01-14
CL2011002703A1 (es) 2012-07-20
KR20120040141A (ko) 2012-04-26
CN102482699A (zh) 2012-05-30
DK2425008T3 (en) 2015-10-05
SG175396A1 (en) 2011-12-29
ME02280B (me) 2016-02-20
EA021512B1 (ru) 2015-07-30
HRP20151352T1 (hr) 2016-01-01
CA2760525A1 (en) 2010-11-04
EP2425008A1 (en) 2012-03-07
AU2010241581A1 (en) 2011-11-17
KR101758713B1 (ko) 2017-07-18
SI2425008T1 (sl) 2015-12-31
NI201100187A (es) 2012-05-24
PE20121493A1 (es) 2012-11-05
EP3020822A1 (en) 2016-05-18
IL215906A0 (en) 2012-01-31
JP2012525425A (ja) 2012-10-22
PT2425008E (pt) 2015-12-04
NZ596036A (en) 2014-03-28
EP2425008A4 (en) 2012-11-07
PL2425008T3 (pl) 2016-03-31
MX2011011623A (es) 2011-11-18
EP2425008B1 (en) 2015-09-16
UA112282C2 (uk) 2016-08-25
MY180699A (en) 2020-12-07
SMT201500293B (it) 2016-01-08
EA201171307A1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
DK2350304T3 (en) TOLL-LIKE RECEPTOR 3-ANTAGONISTS
DK2425008T3 (en) Toll-like receptor antagonists 3
US20130090457A1 (en) Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
US8460659B2 (en) Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
KR20140075708A (ko) 대사 및 심혈관 질환의 치료를 위한 톨-유사 수용체 3 길항제